Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Shigeto Ueda Hitoshi Tsuda Toshiaki Saeki Jiro Omata Akihiko Osaki Takashi Shigekawa Jiro Ishida Katsumi Tamura Yoshiyuki Abe Tomoyu
- چاپ و سال / کشور: 2010
Description
Purpose To assess whether the early metabolic response evaluated by 18F-fluorodeoxy-glucose positron emission combined with computed tomography (FDG PET/CT) predicts the morphological, pathological, and cell-cycle responses to neoadjuvant endocrine therapy of hormone receptor-positive primary breast cancer. Study design Eleven patients (12 tumors) with estrogen receptor-positive (Allred score 7 or 8) primary breast cancer were enrolled. All patients received a daily dose (2.5 mg) of letrozole for 12 weeks followed by surgery. Sequential FDG PET/CT scans were performed before treatment (baseline), at 4 weeks after the initiation of endocrine therapy (PET2), and prior to surgery (PET3). Tumors showing a 40% or more reduction and those showing a less than 40% reduction in the standardized uptake value maximum (SUVmax) at PET2 compared with the baseline PET were defined as metabolic responders and metabolic nonresponders, respectively. Change in tumor size as measured by ultrasound (morphological response), pathological response, and change in the Ki67 labeling index in tumor tissue (cell-cycle response) during the neoadjuvant letrozole therapy were compared between the metabolic responders and nonresponders
Breast Cancer DOI 10.1007/s12282-010-0212-y Received: 22 February 2010 / Accepted: 19 May 2010 The Japanese Breast Cancer Society 2010
